Genetic Technologies: Expanding Portfolio of Disease Risk Tests
May. 18, 2021
Genetic Technologies (Nasdaq: GENE) is a diversified molecular diagnostics company developing tools for the prediction and assessment of cancer risk to help physicians proactively manage patient health. The Company’s lead products, ‘GeneType for Breast Cancer’ and ‘GeneType for Colorectal Cancer’, are clinically validated risk assessment tests that are first in their class. The Company’s development pipeline includes new tests for COVID-19, Type 2 diabetes, cardiovascular disease, prostate cancer, and melanoma. Listed on the ASX in 2000 and NASDAQ in 2005, Genetic Technologies has been a leader in the development and commercialization of genetic risk assessment technology for 20 years. Visit GENEtechinfo.com to learn more.
